Related Experiment Video

Updated: Jun 1, 2026

Quantitative Immunofluorescence Assay to Measure the Variation in Protein Levels at Centrosomes
09:39

Quantitative Immunofluorescence Assay to Measure the Variation in Protein Levels at Centrosomes

Published on: December 20, 2014

Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in

Stefan Duensing1, Sebastian Darr, Rolando Cuevas

  • 1Cancer Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

Genes & Cancer
|June 8, 2011
PubMed

Insights

The protease tripeptidyl peptidase II (TPPII) drives c-MYC-induced centrosome overduplication in human cancers. Inhibiting TPPII suppressed abnormal cell growth and caused cell death, suggesting TPPII as a potential cancer drug target.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Biochemistry

Background:

  • Centrosome aberrations are common in human malignancies associated with the c-MYC oncogene.
  • Understanding the molecular mechanisms driving these aberrations is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of tripeptidyl peptidase II (TPPII) in c-MYC-driven centrosome and centriole overduplication.
  • To evaluate TPPII as a potential therapeutic target in c-MYC-associated cancers.

Main Methods:

  • Localization studies of TPPII at centrosomes.
  • Experimental manipulation of TPPII levels (overexpression, knockdown, chemical inhibition).
  • Assessment of centriole duplication control and cell proliferation/death in cancer cell lines.

Main Results:

  • TPPII localizes to centrosomes and its overexpression mimics c-MYC's effect on centriole overduplication.
  • TPPII inactivation via inhibitors or siRNA significantly reduced c-MYC-induced centriole overduplication.
  • The selective TPPII inhibitor butabindide suppressed centriole aberrations and induced cell death in Burkitt lymphoma cells.

Conclusions:

  • TPPII is a critical mediator of c-MYC-induced centriole overduplication.
  • Targeting TPPII represents a promising novel therapeutic strategy for c-MYC-driven human malignancies.

More Related Videos

Immunofluorescence Analysis of Endogenous and Exogenous Centromere-kinetochore Proteins05:35

Immunofluorescence Analysis of Endogenous and Exogenous Centromere-kinetochore Proteins

Published on: March 3, 2016

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Centrosome Duplication02:25

Centrosome Duplication

The primary microtubule organizing center (MTOC) in animal cells is the centrosome. A centrosome has two cylindrical centrioles at its core. Each centriole consists of nine sets of three microtubules held together by proteins. The centrioles are positioned at right angles to each other and surrounded by a shapeless protein cloud called the pericentriolar matrix, or pericentriolar material (PCM).
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
Centrosome Duplication02:25

Centrosome Duplication

The primary microtubule organizing center (MTOC) in animal cells is the centrosome. A centrosome has two cylindrical centrioles at its core. Each centriole consists of nine sets of three microtubules held together by proteins. The centrioles are positioned at right angles to each other and surrounded by a shapeless protein cloud called the pericentriolar matrix, or pericentriolar material (PCM).
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...